Published in Blood Weekly, April 12th, 2001
"Platelet production is decreased in certain cases of refractory ITP," explained J.B. Bussel and colleagues at Cornell University. "IL-11 stimulates megakaryocytopoiesis in vitro and was licensed for its clinical effects to ameliorate chemotherapy-induced thrombocytopenia."
However, Bussel et al. found that refractory ITP patients realized little if any benefit from rhIL-11 treatment, at the cost...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.